<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>4712</number>
    <updateDate>2023-01-11T13:44:19Z</updateDate>
    <updateDateIncludingText>2023-01-11T13:44:19Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <type>HR</type>
    <introducedDate>2019-10-17</introducedDate>
    <congress>116</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 165, Number 164 (Thursday, October 17, 2019)][House]From the Congressional Record Online through the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]By Ms. DEAN:H.R. 4712.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8 of the U.S. Constitution.[Page H8227]</pre>]]></constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>sshr00</systemCode>
        <name>Health, Education, Labor, and Pensions Committee</name>
        <chamber>Senate</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2020-11-18T18:42:22Z</date>
          </item>
        </activities>
      </item>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <subcommittees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
            <activities>
              <item>
                <name>Reported by</name>
                <date>2020-03-11T14:04:52Z</date>
              </item>
              <item>
                <name>Markup by</name>
                <date>2020-03-11T13:55:06Z</date>
              </item>
              <item>
                <name>Referred to</name>
                <date>2019-10-18T18:11:41Z</date>
              </item>
            </activities>
          </item>
        </subcommittees>
        <activities>
          <item>
            <name>Reported by</name>
            <date>2020-11-16T20:06:05Z</date>
          </item>
          <item>
            <name>Markup by</name>
            <date>2020-07-15T13:25:40Z</date>
          </item>
          <item>
            <name>Referred to</name>
            <date>2019-10-17T14:02:10Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <committeeReports>
      <committeeReport>
        <citation>H. Rept. 116-572</citation>
      </committeeReport>
    </committeeReports>
    <relatedBills>
      <item>
        <title>Fairness in Orphan Drug Exclusivity Act</title>
        <congress>116</congress>
        <number>3271</number>
        <type>S</type>
        <latestAction>
          <actionDate>2020-02-11</actionDate>
          <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2020-11-18</actionDate>
        <committees>
          <item>
            <systemCode>sshr00</systemCode>
            <name>Health, Education, Labor, and Pensions Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <name>Senate</name>
        </sourceSystem>
        <text>Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
        <type>IntroReferral</type>
      </item>
      <item>
        <actionDate>2020-11-17</actionDate>
        <actionTime>12:36:58</actionTime>
        <text>Motion to reconsider laid on the table Agreed to without objection.</text>
        <type>Floor</type>
        <actionCode>H38310</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2020-11-17</actionDate>
        <actionTime>12:36:54</actionTime>
        <text>On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5807)</text>
        <type>Floor</type>
        <actionCode>H37300</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2020-11-17</actionDate>
        <actionTime>12:36:54</actionTime>
        <text>Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5807)</text>
        <type>Floor</type>
        <actionCode>8000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2020-11-17</actionDate>
        <actionTime>12:25:47</actionTime>
        <text>DEBATE - The House proceeded with forty minutes of debate on H.R. 4712.</text>
        <type>Floor</type>
        <actionCode>H8D000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2020-11-17</actionDate>
        <actionTime>12:25:42</actionTime>
        <text>Considered under suspension of the rules. (consideration: CR H5807-5809)</text>
        <type>Floor</type>
        <actionCode>H30000</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2020-11-17</actionDate>
        <actionTime>12:25:15</actionTime>
        <text>Mr. Pallone moved to suspend the rules and pass the bill, as amended.</text>
        <type>Floor</type>
        <actionCode>H30300</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2020-11-16</actionDate>
        <text>Placed on the Union Calendar, Calendar No. 470.</text>
        <type>Calendars</type>
        <actionCode>H12410</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <calendarNumber>
          <calendar>U00470</calendar>
        </calendarNumber>
      </item>
      <item>
        <actionDate>2020-11-16</actionDate>
        <text>Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-572.</text>
        <type>Committee</type>
        <actionCode>H12200</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2020-11-16</actionDate>
        <text>Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-572.</text>
        <type>Committee</type>
        <actionCode>5000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2020-07-15</actionDate>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Ordered to be Reported (Amended) by Voice Vote.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2020-07-15</actionDate>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Committee Consideration and Mark-up Session Held.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2020-03-11</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2020-03-11</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Subcommittee Consideration and Mark-up Session Held.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2019-10-18</actionDate>
        <committees>
          <item>
            <systemCode>hsif14</systemCode>
            <name>Health Subcommittee</name>
          </item>
        </committees>
        <sourceSystem>
          <code>1</code>
          <name>House committee actions</name>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionDate>2019-10-17</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2019-10-17</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2019-10-17</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>D000631</bioguideId>
        <fullName>Rep. Dean, Madeleine [D-PA-4]</fullName>
        <firstName>Madeleine</firstName>
        <lastName>Dean</lastName>
        <party>D</party>
        <state>PA</state>
        <district>4</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>V000131</bioguideId>
        <fullName>Rep. Veasey, Marc A. [D-TX-33]</fullName>
        <firstName>Marc</firstName>
        <lastName>Veasey</lastName>
        <party>D</party>
        <state>TX</state>
        <middleName>A.</middleName>
        <district>33</district>
        <sponsorshipDate>2019-10-17</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>C001103</bioguideId>
        <fullName>Rep. Carter, Earl L. "Buddy" [R-GA-1]</fullName>
        <firstName>Earl</firstName>
        <lastName>Carter</lastName>
        <party>R</party>
        <state>GA</state>
        <middleName>L. "Buddy"</middleName>
        <district>1</district>
        <sponsorshipDate>2019-10-17</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>M001180</bioguideId>
        <fullName>Rep. McKinley, David B. [R-WV-1]</fullName>
        <firstName>David</firstName>
        <lastName>McKinley</lastName>
        <party>R</party>
        <state>WV</state>
        <middleName>B.</middleName>
        <district>1</district>
        <sponsorshipDate>2019-10-17</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>T000469</bioguideId>
        <fullName>Rep. Tonko, Paul [D-NY-20]</fullName>
        <firstName>Paul</firstName>
        <lastName>Tonko</lastName>
        <party>D</party>
        <state>NY</state>
        <district>20</district>
        <sponsorshipDate>2019-12-05</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>K000394</bioguideId>
        <fullName>Rep. Kim, Andy [D-NJ-3]</fullName>
        <firstName>Andy</firstName>
        <lastName>Kim</lastName>
        <party>D</party>
        <state>NJ</state>
        <district>3</district>
        <sponsorshipDate>2020-07-16</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>S001200</bioguideId>
        <fullName>Rep. Soto, Darren [D-FL-9]</fullName>
        <firstName>Darren</firstName>
        <lastName>Soto</lastName>
        <party>D</party>
        <state>FL</state>
        <district>9</district>
        <sponsorshipDate>2020-08-04</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>T000479</bioguideId>
        <fullName>Rep. Taylor, Van [R-TX-3]</fullName>
        <firstName>Van</firstName>
        <lastName>Taylor</lastName>
        <party>R</party>
        <state>TX</state>
        <district>3</district>
        <sponsorshipDate>2020-11-16</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Competition and antitrust</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Licensing and registrations</name>
        </item>
        <item>
          <name>Marketing and advertising</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2019-10-17</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2021-09-07T20:45:00Z</updateDate>
        <text><![CDATA[ <p><b>Fairness in Orphan Drug Exclusivity Act</b><br /></p> <p>This bill limits which orphan drugs may be granted a market exclusivity period by the Food and Drug Administration (FDA). (Generally, an orphan drug is one that is not economically viable because of the rarity of the disease that it treats; the sponsor of an FDA-designated orphan drug may be granted various incentives, such as a seven-year period in which the FDA may not grant market approval to a different sponsor for the same drug to treat the same disease.)</p> <p>Specifically, when determining whether to grant an exclusivity period to a drug that has orphan status due to low expected sales, the FDA shall consider the sales of all drugs from the sponsor that have the same core molecule or ion that is responsible for the drug's physiological or pharmacological action.</p>]]></text>
      </summary>
      <summary>
        <versionCode>07</versionCode>
        <actionDate>2020-11-16</actionDate>
        <actionDesc>Reported to House</actionDesc>
        <updateDate>2021-09-07T20:49:50Z</updateDate>
        <text><![CDATA[ <p><b>Fairness in Orphan Drug Exclusivity Act</b></p> <p>This bill limits which orphan drugs may be granted a market exclusivity period by the Food and Drug Administration (FDA). (Generally, an orphan drug is one that is not economically viable because of the rarity of the disease that it treats; the sponsor of an FDA-designated orphan drug may be granted various incentives, such as a seven-year period in which the FDA may not grant market approval to a different sponsor for the same drug to treat the same disease.)</p> <p>Under this bill, if a drug is designated as an orphan drug on the basis that there is no reasonable expectation that the sponsor will recover the costs of developing and distributing the drug from U.S. sales, the drug shall be granted the seven-year exclusivity period only if the sponsor demonstrates that there is no reasonable expectation that it will recover such costs specifically within its first 12 years of U.S. sales of the drug. This requirement shall also apply retroactively to an orphan drug that was granted such an exclusivity period before this bill's enactment. </p> <p>When deciding whether an orphan drug meets this requirement, the FDA shall consider the sales of all drugs from the sponsor that are covered by the same orphan drug designation.</p>]]></text>
      </summary>
      <summary>
        <versionCode>53</versionCode>
        <actionDate>2020-11-17</actionDate>
        <actionDesc>Passed House</actionDesc>
        <updateDate>2021-09-07T20:50:47Z</updateDate>
        <text><![CDATA[ <p><b>Fairness in Orphan Drug Exclusivity Act</b></p> <p>This bill limits which orphan drugs may be granted a market exclusivity period by the Food and Drug Administration (FDA). (Generally, an orphan drug is one that is not economically viable because of the rarity of the disease that it treats; the sponsor of an FDA-designated orphan drug may be granted various incentives, such as a seven-year period in which the FDA may not grant market approval to a different sponsor for the same drug to treat the same disease.)</p> <p>Under this bill, if a drug is designated as an orphan drug on the basis that there is no reasonable expectation that the sponsor will recover the costs of developing and distributing the drug from U.S. sales, the drug shall be granted the seven-year exclusivity period only if the sponsor demonstrates that there is no reasonable expectation that it will recover such costs specifically within its first 12 years of U.S. sales of the drug. This requirement shall also apply retroactively to an orphan drug that was granted such an exclusivity period before this bill's enactment. </p> <p>When deciding whether an orphan drug meets this requirement, the FDA shall consider the sales of all drugs from the sponsor that are covered by the same orphan drug designation.</p>]]></text>
      </summary>
    </summaries>
    <title>Fairness in Orphan Drug Exclusivity Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Fairness in Orphan Drug Exclusivity Act</title>
      </item>
      <item>
        <titleType>Short Title(s) as Passed House</titleType>
        <title>Fairness in Orphan Drug Exclusivity Act</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Engrossed in House</billTextVersionName>
        <billTextVersionCode>EH</billTextVersionCode>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs, and for other purposes.</title>
        <billTextVersionName>Reported in House</billTextVersionName>
        <billTextVersionCode>RH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Titles as Passed House</titleType>
        <title>Fairness in Orphan Drug Exclusivity Act</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Fairness in Orphan Drug Exclusivity Act</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Reported to House</titleType>
        <title>Fairness in Orphan Drug Exclusivity Act</title>
        <chamberCode>H</chamberCode>
        <chamberName>House</chamberName>
        <billTextVersionName>Reported in House</billTextVersionName>
        <billTextVersionCode>RH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Referred in Senate</type>
        <date>2020-11-18T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116hr4712rfs/xml/BILLS-116hr4712rfs.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Engrossed in House</type>
        <date>2020-11-17T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116hr4712eh/xml/BILLS-116hr4712eh.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Reported in House</type>
        <date>2020-11-16T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116hr4712rh/xml/BILLS-116hr4712rh.xml</url>
          </item>
        </formats>
      </item>
      <item>
        <type>Introduced in House</type>
        <date>2019-10-17T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116hr4712ih/xml/BILLS-116hr4712ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2020-11-18</actionDate>
      <text>Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
